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Abstract - In our study we investigated the role of the estrogen receptor (ER), progesterone receptor (PR) and clinico-
histological parameters in breast cancer patients treated with tamoxifen during the early (2.5 years) vs. late (2.5-5 years) 
follow-up. The negative status of both ER and PR and tumors equal to or bigger than 2 cm defined the phenotypes and 
consequently the groups of patients with the worst clinical course of the disease: ER-negative PR-negative, ER-negative 
pT2 and PR-negative pT2. These high-risk subgroups were related to early follow-up indicating de novo resistance. It is 
relevant to point out that examined predictive indicators did not show significant importance in the late follow-up 
study.  
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INTRODUCTION 
Nearly 70% of breast tumors express estrogen (ER) 
and progesterone (PR) receptors (Massarweh, 
2006). For this reason endocrine therapies have 
been used for more than a 100 years and they are 
the most effective treatment for breast cancers 
(Osborne, 2006). For almost 20 years the standard 
therapy for patients expressing ER/PR is the one 
with SERMs (selective estrogen-receptor modu-
lators), which are designed to block the ER function 
(EBCTCG, 2005). The most potent SERM is 
tamoxifen, which was approved for use in advanced 
breast cancer (Jordan, 1994). In the years after, 
tamoxifen was established as the best endocrine 
therapy for the adjuvant treatment of primary 
breast cancers (Osborne, 1998). Although it signi-
ficantly reduces distant metastasis and the death of 
breast cancer patients who received tamoxifen for 5 
years, the problem of early (de novo) as well as late 
(acquired) resistance is still important. With the 
first presentation to tamoxifen therapy only 50% of 
ER-positive tumors are responsive and after some 
time the responsive tumors can become resistant, 
leading to breast cancer progression and death 
(Osborne, 1998). In light of these problems with 
classical SERM drugs, today we have a new 
generation of anticancer agents. Aromatase inhibi-
tors can reduce the level of estrogen and inhibit the 
ligand-induced activation of ER. A SERD (selective 
ER downregulator) like fulvestrant can bind to the 
ER, completely blocking its function and inducing 
its degradation (Campos, 2003; Osborne, 2000; 
Baum, 2003; Buzdar, 2003). 
Postmenopausal patients with ER-positive 
breast cancer, who have undergone surgical treat-
ment, are the best candidates for adjuvant treat-
ment with tamoxifen. Current studies indicate that 
the most critical period for the occurrence of dis-
tant metastasis is the first 2.5 years after diagnosis 
(Mansell, 2008). This finding is supported by a large 
study by Saphner et al., (Saphner, 1996) in a large 
cohort of patients (n=3,585). Houghton and col-
leagues (Houghton, 2006) have reported similar 
results in an Arimidex, Tamoxifen, Alone or in 
Combination (ATAC) trial. An explanation of the 
possible reasons for endocrine resistance is given by 
a growing investigation of the cross-talk between 
the signaling pathways of steroid receptors and 
growth factor receptors. The estrogen receptor is a 
well-established predictor in the case of endocrine 250  Z. ABU RABI ET AL. 
Table 1. Histological characteristics of breast carcinomas
 
therapy, but the role of PR is more controversial 
(Rakha, 2007). It is much easier to decide between 
treatment strategies in the case of double positive or 
negative phenotypes than in the case of ER-posi-
tive/PR-negative or ER-negative/PR-positive tu-
mors.  
Today, the presence of multiple endocrine 
therapies provides us with the opportunity to 
choose among different treatment strategies. The 
timing of the occurrence of distant metastasis has 
great clinical relevance and it can help clinicians to 
decide which kind of therapy each patient should 
receive (Kennecke, 2008). In our study, we analyzed 
the molecular biomarkers ER and PR and clinical-
histological characteristics of breast cancers in 
order to subgroup patients with an increased risk of 
early vs. late occurrence of distant metastasis in the 
group of postmenopausal patients bearing breast 
carcinomas with detectable ER. 
PATIENTS AND METHODS 
Patients 
Our study included 113 patients with histologically 
verified primary operable breast carcinomas. All of 
the patients were postmenopausal women who 
received adjuvant tamoxifen therapy. The course of 
the disease was followed for 5 years, for each 
individual patient. The patient’s follow-up was 
conducted every 3 months during the first 2 years, 
and every 6 months during the next 3 years. After 
the curative surgery, tumor samples were stored in 
liquid nitrogen, until assayed. 
Methods 
Clinical-histological  predictive parameters: The 
age and the menopausal status were obtained from 
each patient’s medical record. A patient was 
considered to be postmenopausal if menstruation 
had been absent for at least six months. The 
patients’ age ranged from 43 to 81 years, with a 
median age of 62. Histological specimens were 
reviewed and then classified according to the 
criteria of the International Union Against Cancer 
for TN stages (UICC, 1987) and the histological 
type (Scarf, 1968). The histological characteristics of 
breast carcinomas are shown in Table 1. 
Molecular biomarkers: ER and PR 
quantitative values were measured by the classical 
biochemical method as recommended by the 
EORTC (EORTC, 1980). The intra-laboratory 
quality assessment of the steroid hormone 
receptor levels was performed periodically 
following the EORTC recommendation (1995). 
The cut-off value for both ER and PR expression 
was defined as 5 fmol/mg and was obtained for 
the follow up period of 2.5 years. The statistically 
significant differences in probabilities of disease-
free intervals (DFI) for discriminating the 
positive and negative status of ER and PR were 
attained by the gradual examination of both 
quantitative values as predictive indicators in 
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Figure 1. Disease-free interval probability as a function of the
ER and PR status in patients with breast carcinoma in the first
2.5 years of follow up study 
Table 2. Steroid hormone receptor values (range, median) in 
breast carcinomas 
Statistical evaluations: The probabilities of a 
disease-free interval were estimated using the 
Kaplan-Meier method and were compared by the 
log-rank test. The correlation between the 
quantitative values of ER and PR was examined by 
the Spearman rank correlation test. A P value less 
than 0.05 was considered as statistically significant. 
RESULTS 
One hundred and thirteen patients were included in 
this investigation. All of these patients had detectable 
levels of ER and PR in breast carcinomas and had 
undergone the adjuvant tamoxifen therapy after 
surgical treatment. The course of the disease for all 
patients was followed until the occurrence of distant 
metastasis (distant metastasis as an end point), with a 
follow-up period of 60 months. Our focus in the study 
was directed to two subgroups of patients. The first 
one included patients who were analyzed within the 
first 2.5 years of the follow-up period. The second 
subgroup consisted of patients who were disease-free 
after the 2.5 years of follow-up, and who were 
monitored until the end of the follow-up period. The 
ranges and median values of the ER and PR levels are 
given in Table 2. A positive correlation was found 
between the ER and PR levels in the whole group of 
patients (p<0.001, data not shown).  
The course of disease for the first 2.5- year period of 
the follow-up study 
The DFI probabilities for the subgroups of patients 
according to the cut-off value reached a statistically 
significant difference in the case of ER (p=0.002, 
data not shown). The subgroup of patients with po-
sitive ER status (n=100) had higher DFI pro-
babilities. Similar results were obtained for PR 
(p<0001) where the PR-positive subgroup of 
patients (n=91) had statistically significantly higher 
probabilities of DFI (data not shown). 
Of the classical clinical-histological parameters, 
lymph node status, histological type and the 
histological grade of the tumors did not cause 
differences in the analyses of DFI probabilities (data 
not shown). The tumor size defined two subgroups 
of patients with pT1 (n=58) showing a statistically 
significantly better prediction than pT2 patients 
(n=53, p=0.03, data not shown).  
By combining the ER and PR statuses, we ob-
tained four phenotypes (Figure 1). The best response 
to tamoxifen therapy was obtained for the ER-
positive PR-positive subgroup of patients (n=85), 
while the worst subgroup of patients, in terms of the 
success of this therapy, was the one with the ER-
negative PR-negative phenotype (n=7). We found 
statistically significant differences in DFI proba-
bilities between the low risk subgroup of patients 
(ER-positive PR-positive), and both the ER-negative 252  Z. ABU RABI ET AL. 
Figure 2. Disease-free interval probability as a function of the
pT and ER status in patients with breast carcinoma in the first
2.5 years of follow up study 
Figure 3. Disease-free interval probability as a function of the
pT and PR status in patients with breast carcinoma in the first 
2.5 years of follow up study 
PR-negative (p<0.001), and the ER-positive PR-
negative (n=15, p=0.01) subgroups of patients.  
We also investigated the course of disease of 
four phenotypes defined by tumor size and ER 
status (Figure 2). Out of these four phenotypes, the 
patients with large tumors (pT2) with ER-negative 
status (n=10) had the worst course of the disease. 
There was a statistically significant difference in the 
DFI probabilities between the ER-positive pT1 
(n=55) and ER-negative pT2 subgroups of patients 
(p<0.001). Comparison of the patients with large 
tumors (pT2) and either positive (n=42) or negative 
ER status revealed a statistically significant diffe-
rence in the DFI probabilities (p=0.003). The ER-
negative pT1 subgroup had only 3 patients so we 
did not include it in our analysis.  
By comparing the subgroups of patients defined 
by tumor size and PR status, we found statistically 
significant differences in the DFI probabilities bet-
ween the following subgroups of patients: PR-posi-
tive pT1 (n=47) vs. PR-negative pT1(n=11, p=0.03); 
PR-positive pT1- vs. PR-negative pT2 (n=11, 
p<0.001), and PR-positive pT2 (n=42) vs. PR-
negative pT2 (p=0.01) (Fig. 3).  
The course of disease for the period of 2.5-5-years 
of the follow up study 
There were no significant differences in the DFI 
probabilities between the subgroups of patients 
defined by tumor size, histological type and grade, 
or lymph node status. Statistically significant dif-
ferences in the DFI probabilities determined within 
the first 2.5 years of the follow-up study, for the 
subgroups of patients defined by ER and PR status, 
are lost (data not shown). 
The comparison of the DFI probabilities for 
patients with tumors of different size and with dif-
ferent PR status revealed no statistically significant 
differences (data not shown). The subgroups of 
patients (PR-positive pT1 or pT2 and PR-negative 
pT1 or pT2) caused no statistically significant 
differences, as seen from the analysis within the first 
2.5 years of the follow-up study (data not shown).  
DISCUSSION 
It is well known that breast carcinomas are a hete-
rogeneous group with distinctive molecular cha-
racteristics, aggressiveness and response to therapy.   TAMOXIFEN RESISTANCE IN BREAST CANCER  253 
There are limited data in identifying subgroups of 
postmenopausal breast cancer patients who are at the 
highest risk of early occurrence of distant metastasis 
and who could benefit from the different additive 
endocrine treatment approach (Mansell, 2008). 
The main purpose of our study was to deter-
mine the importance of the quantitative values of 
the ER and PR expression and clinico-histological 
characteristics of breast carcinomas in the emer-
gence of distant metastasis in postmenopausal 
breast cancer patients. A secondary objective was to 
identify the different breast cancer phenotypes that 
could point to the early (de novo) or late (acquired) 
resistance to tamoxifen. 
Evaluating the relevance of the ER and PR 
status within the first 2.5 years of the follow-up 
period, we found that these biomarkers were in-
dependent predictors of early resistance. The nega-
tive ER and PR status points to an early occurrence 
of distant metastasis, making the ER and PR strong 
predictors in relation to tamoxifen treatment, as 
shown in some studies (Mauriac, 2007; Kennecke, 
2008). The tumor size indicates a poor prediction 
for larger tumors, pT2, consistent with the study of 
Mansell et al., (Mansell, 2008). The power of ER, PR 
and tumor size as predictors is lost after the initial 
2.5 years of tamoxifen therapy. Lymph node status, 
histological grade and type of tumor did not addi-
tionally subgroup the patients. Considering treat-
ment strategies, it is much easier to decide in the 
case of the double positive/negative phenotypes 
than in case of single-positive phenotypes. It has 
been reported that 75-85% of tumors with the 
double-positive phenotype respond to hormonal 
manipulation, whereas only 40% of the single-posi-
tive phenotypes respond in the same way (Dowsett, 
2006). In the subgroup of ER-positive tumors, 
among postmenopausal patients there is conside-
rable evidence of the significant predictive power of 
PR (Ponzone, 2006; Cui, 2005). It is shown that PR 
negativity is a marker of early (de novo) tamoxifen 
resistance during the first 3 years of treatment and 
that there is a decline of risk after the first 3 years 
(Tovey, 2005). Similar results are reported in the 
ATAC trial where it was confirmed that the PR 
status defines a group of tumors with distinctive 
pathological features that can benefit from a more 
aggressive approach or a different kind of therapy 
(Dowsett, 2005). 
When the four phenotypes defined by ER and 
PR status were analyzed, the ER-positive PR-
negative phenotype had lower probabilities of DFI 
than ER-positive PR-positive tumors, as seen in the 
ATAC trial (Dowsett, 2005). The expression of PR 
gives an additional predictive value to ER. There are 
several explanations for the ER-positive PR-ne-
gative phenotype. Since the expression of PR is ER-
dependent, the simplest explanation is that the ER 
is non-functional and unable to stimulate PR 
production, so the tumor is no longer dependent on 
estrogen for growth and survival (Cui, 2005). But, 
as proven in the recent trial, ER-positive PR-ne-
gative tumors respond much better to estrogen 
withdrawal than to tamoxifen (Dowsett, 2003). This 
indicates that these tumors are still estrogen 
dependent and that the loss of ER function is not 
the whole explanation for resistance to tamoxifen 
(Cui, 2005). 
There are three possible explanations for this 
phenomenon. The first one is the repression of the 
PR gene by methylation of the PR promoter region, 
which is present in 21-40% of ER-positive PR-
negative tumors (Lapidus, 1998; Cui, 2005). The 
second explanation is the loss of heterozygosity 
(LOH) at the PR gene locus (chromosome 11q23), 
which occurs in approximately 40% of primary 
breast cancers and is associated with the loss of PR 
protein expression (Tomlinson, 1996; Winqvist, 
1995). Nevertheless, these two assumptions failed to 
elucidate the resistance to tamoxifen therapy in the 
group of patients with ER-positive PR-negative tu-
mors. The third, and the most likely explanation, is 
that in the presence of growth factor receptor 
overexpression, the P13K-Akt-mTor pathway can 
be triggered. The activation of this path leads to a 
reduction of PR on the transcriptional level, with 
the AP-1 repression of the PR promoter (Petz, 
2004). The consequence of this signal transduction 
pathway can be the phosphorylation of ER and, 
thus, the enhancement of the known agonistic acti-254  Z. ABU RABI ET AL. 
vity of tamoxifen, which can lead to proliferation 
and resistance to therapy (Campbell, 2001). This 
growth factor signaling can be amplified even more 
by switching from nuclear to membrane-initiated 
steroid signaling of ER (Cui, 2005). The same effect 
of growth factor signaling on the PR expression was 
confirmed in some in vitro studies (Konecny, 2003; 
McClelland, 2001).  
Our results also show a sharp decrease of 
significance of the PR status after 2.5 years of the 
follow-up period. This indicates that PR is a time-
dependent predictor of the risk of the appearance of 
distant metastasis. This assumption is confirmed in 
the study of Coombes et al., (Coombes, 2004). 
Analysis of the DFI probabilities, within the pheno-
types defined by ER status and tumor size, revealed 
a high-risk group of patients bearing larger tumors 
with a negative status of ER. The estrogen receptor 
status can additionally subgroup patients within the 
pT2 group. The statistically significant differences 
in the DFI probabilities between the ER-negative 
pT2 and other phenotypes were also diminished 
after 2.5 years of the follow-up study. On the other 
hand, the PR status enables the subgrouping of 
patients within both the pT1 and pT2 subgroups of 
patients during the first 2.5 years of the follow up. 
To summarize, our research confirmed a sig-
nificant role of the ER and tumor size as predictive 
parameters. By combining these parameters, we can 
obtain additional information regarding the 
patients’ prognosis. The estrogen receptor is still the 
most powerful predictive biochemical marker in 
terms of tamoxifen therapy. But our study confirms 
that the PR is also a significant predictive marker 
that can possibly indicate the aberrant growth 
factor signaling in the group of ER-positive 
patients. Our data support the conclusion that ER-
positive PR-negative and pT2 either ER- or PR- 
negative patients constitute subgroups with a high 
risk of de novo tamoxifen resistance. This ER-, PR- 
and pT- related risk is indubitable time-dependent 
and confined to the first 2.5 year of the therapy. 
Other prospective clinical trials are required in 
order to define the short- and long-term hormone 
therapeutic strategies tailored for each ER-positive 
breast cancer patient.  
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РАНА И КАСНА РЕЗИСТЕНЦИЈА НА ТАМОКСИФЕН КОД КАНЦЕРА ДОЈКЕ 
З. АБУ РАБИ, М. МАРКИЋЕВИЋ, ТИЈАНА ВУЈАСИНОВИЋ, СИЛВАНА ЛУКИЋ, 
ЉИЉАНА СТАМАТОВИЋ и ДРАГИЦА НИКОЛИЋ-ВУКОСАВЉЕВИЋ 
Институт за онкологију и радиологију Србије, 11000 Београд, Србија 
У студији је испитивана улога ER, PR и 
клиничко-хистолошких  параметара у групи 
болесница оболелих од карцинома дојке, 
лечених тамоксифеном, током раног (2,5 
године) и касног (2,5-5 година) периода праћења 
тока болести. Негативни статуси ER и PR и 
величина тумора једнака или већа од 2 цм су 
дефинисали фенотипове, односно подгрупе 
болесница, са најлошијим клиничким током 
болести: ER-негативан PR-негативан, ER-
негативан pТ2 и PR-негативан pT2. Наведене 
високо-ризичне подгрупе болесница су биле 
повезане са раним периодом праћења тока 
болести што указује на де ново резистенцију. 
Релевантно је истаћи да истраживани 
предиктивни индикатори нису показали 
значајност у касном периоду праћења тока 
болести. 
 